NCT06328491View on ClinicalTrials.gov

Erdafitinib in Metastatic Steroid-cell Ovarian Cancer

NACompletedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

May 30, 2022

Primary Completion Date

August 22, 2022

Study Completion Date

August 22, 2022

Conditions

Ovarian CancerSteroid Cell Tumor, Malignant

Interventions

DRUG

Erdafitinib

Protein Kinase Inhibitor

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors

lead

University Health Network, Toronto

OTHER